Literature DB >> 15748867

The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.

Takao Yasuhara1, Tetsuro Shingo, Kenichiro Muraoka, Yuan wen Ji, Masahiro Kameda, Akira Takeuchi, Akimasa Yano, Shinsaku Nishio, Toshihiro Matsui, Yasuyuki Miyoshi, Hirofumi Hamada, Isao Date.   

Abstract

Vascular endothelial growth factor (VEGF) has previously been shown to display neuroprotective effects on dopaminergic (DA) neurons. In this study, we investigated whether the effects of VEGF were dose-dependent or not. First, VEGF was shown to be neuroprotective on 6-hydroxydopamine (6-OHDA)-treated murine DA neurons in vitro, although the 1 ng/ml of VEGF displayed more neuroprotective effects than 100 ng/ml. Furthermore, using 2 sizes of capsules (small/large) with different secreting quantities, 6-OHDA-treated rats receiving the small capsule filled with VEGF-secreting cells (BHK-VEGF) into the striatum showed a significant decrease in amphetamine-induced rotational behavior in number and a significant preservation of TH-positive fibers compared to those receiving the large BHK-VEGF capsule as well as those receiving BHK-Control capsule. Rats receiving the large BHK-VEGF capsule showed much more glial proliferation, angiogenesis, and brain edema around the capsule than those with the small one. High-dose administration of VEGF might cause poor circulation related to brain edema, although low-dose administration of VEGF displays neuroprotective effects on DA neurons. Our results demonstrate the importance of administration dose of VEGF, suggesting that low-dose administration of VEGF might be desirable for Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748867     DOI: 10.1016/j.brainres.2004.12.055

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

Review 1.  Spatiotemporal control over growth factor signaling for therapeutic neovascularization.

Authors:  Lan Cao; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

2.  Association of VEGF gene polymorphisms with sporadic Parkinson's disease in Chinese Han population.

Authors:  Yubin Wu; Yingying Zhang; Xun Han; Xiaoyuan Li; Li Xue; Anmu Xie
Journal:  Neurol Sci       Date:  2016-08-01       Impact factor: 3.307

3.  Survival, differentiation, and neuroprotective mechanisms of human stem cells complexed with neurotrophin-3-releasing pharmacologically active microcarriers in an ex vivo model of Parkinson's disease.

Authors:  Nicolas Daviaud; Elisa Garbayo; Laurence Sindji; Alberto Martínez-Serrano; Paul C Schiller; Claudia N Montero-Menei
Journal:  Stem Cells Transl Med       Date:  2015-04-29       Impact factor: 6.940

4.  Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.

Authors:  Brinda Desai Bradaric; Aditiben Patel; Julie A Schneider; Paul M Carvey; Bill Hendey
Journal:  J Neural Transm (Vienna)       Date:  2011-07-12       Impact factor: 3.575

5.  Activation of the central histaminergic system is involved in hypoxia-induced stroke tolerance in adult mice.

Authors:  Yan-ying Fan; Wei-wei Hu; Hai-bin Dai; Jian-xiang Zhang; Lu-yi Zhang; Ping He; Yao Shen; Hiroshi Ohtsu; Er-qing Wei; Zhong Chen
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-30       Impact factor: 6.200

Review 6.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

Review 7.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

8.  Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury.

Authors:  Janette M Krum; Nina Mani; Jeffrey M Rosenstein
Journal:  Exp Neurol       Date:  2008-04-03       Impact factor: 5.330

9.  Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice.

Authors:  Sungju Park; Hyoung-Tae Kim; Seokkwan Yun; Il-Sun Kim; Jiyoon Lee; Il-Shin Lee; Kook In Park
Journal:  Exp Mol Med       Date:  2009-07-31       Impact factor: 8.718

10.  PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel microcarriers.

Authors:  Torsten Falk; Nicole R Congrove; Shiling Zhang; Alexander D McCourt; Scott J Sherman; Brian S McKay
Journal:  J Biomed Biotechnol       Date:  2012-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.